TY  - JOUR
AU  - Buntrock, Claudia
AU  - Lehr, Dirk
AU  - Smit, Filip
AU  - Horvath, Hanne
AU  - Berking, Matthias
AU  - Spiegelhalder, Kai
AU  - Riper, Heleen
AU  - Ebert, David Daniel
PY  - 2021
DA  - 2021/5/24
TI  - Guided Internet-Based Cognitive Behavioral Therapy for Insomnia: Health-Economic Evaluation From the Societal and Public Health Care Perspective Alongside a Randomized Controlled Trial
JO  - J Med Internet Res
SP  - e25609
VL  - 23
IS  - 5
KW  - insomnia
KW  - internet-based cognitive behavioural therapy
KW  - iCBT-I
KW  - economic evaluation
KW  - cost-effectiveness
KW  - cost-utility
KW  - cognitive behavioral therapy
KW  - behavior
KW  - sleep
KW  - economics
KW  - public health
KW  - perspective
AB  - Background: The evidence base for internet-based cognitive behavioral therapy for insomnia (iCBT-I) is firm; however, little is known about iCBT-I’s health-economic effects. Objective: This study aimed to evaluate the cost-effectiveness and cost–utility of iCBT-I in reducing insomnia among schoolteachers. Methods: Schoolteachers (N=128) with clinically significant insomnia symptoms and work-related rumination were randomized to guided iCBT-I or a wait list control group, both with unrestricted access to treatment as usual. Health care use, patient and family expenditures, and productivity losses were self-assessed and used for costing from a societal and a public health care perspective. Costs were related to symptom-free status (score <8 on the insomnia severity index) and quality-adjusted life years (QALYs) gained. Sampling error was handled using nonparametric bootstrapping. Results: Statistically significant differences favoring the intervention group were found for both health outcomes (symptom-free status yes or no: β=.30; 95% CI 0.16-0.43; QALYs: β=.019, 95% CI 0.01-0.03). From a societal perspective, iCBT-I had a 94% probability of dominating the wait list control for both health outcomes. From a public health care perspective, iCBT-I was more effective but also more expensive than the wait list control, resulting in an incremental cost-effectiveness ratio of €650 per symptom-free individual. In terms of QALYs, the incremental cost-effectiveness ratio was €11,285. At a willingness-to-pay threshold of €20,000 per QALY gained, the intervention’s probability of being cost-effective was 89%. Conclusions: Our trial indicates that iCBT could be considered as a good value-for-money intervention for insomnia. Trial Registration: German Clinical Trial Registry: DRKS00004700; https://tinyurl.com/2nnk57jm International Registered Report Identifier (IRRID): RR2-10.1186/1745-6215-14-169 
SN  - 1438-8871
UR  - https://www.jmir.org/2021/5/e25609
UR  - https://doi.org/10.2196/25609
UR  - http://www.ncbi.nlm.nih.gov/pubmed/34028361
DO  - 10.2196/25609
ID  - info:doi/10.2196/25609
ER  -